Research map: Diminished Prognostic Value of Interim PET in Hodgkin Lymphoma Treated with Brentuximab Vedotin Plus AVD: A Retrospective Analysis

Back to the article

Papers in this map

  1. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification · Bruce D. Cheson · 2014 · 5729 citations · Cited by this paper
  2. Concomitant Clonal CBFB::MYH11 and PDGFRB Fusions in a Case of De Novo Acute Myeloid Leukemia · 2026 · Related
  3. Early Interim 2-[ 18 F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study · Andrea Gallamini · 2007 · 845 citations · Cited by this paper
  4. Complexities in the Diagnostic Evaluation and Treatment of Infant Hemophagocytic Lymphohistiocytosis · 2026 · Related
  5. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma · Peter Johnson · 2016 · 817 citations · Cited by this paper
  6. The Utility of IgG4/IgG Ratio in the Diagnosis of Multicentric Castleman Disease: A Case Report of HHV8+ Castleman Disease in a Patient with Classical Hodgkin’s Lymphoma · 2026 · Related
  7. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma · Joseph M. Connors · 2017 · 791 citations · Cited by this paper
  8. Paraneoplastic Neuro-Ophthalmologic Symptoms as Initial Manifestation of Hodgkin Lymphoma · 2026 · Related
  9. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma · John A. Radford · 2015 · 761 citations · Cited by this paper
  10. Advances in Gene Therapy for Inherited Haemoglobinopathies · 2025 · Related
  11. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma · Martin Hutchings · 2005 · 725 citations · Cited by this paper
  12. Inherited Platelet Disorders During Pregnancy and Delivery: Overview of Management Strategies and Emerging Therapeutic Considerations · 2026 · Related
  13. Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial · Marc P.E. André · 2017 · 540 citations · Cited by this paper
  14. Primary Bone Lymphoma of the Jaw Masquerading as Infection and Delaying Treatment · 2026 · Related
  15. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group · Peter Borchmann · 2017 · 395 citations · Cited by this paper
  16. Clinical Experience with Emicizumab and Rituximab as First-Line Treatment in a Case Series of Acquired Hemophilia A · 2026 · Related
  17. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma · Stephen Maxted Ansell · 2022 · 352 citations · Cited by this paper
  18. Quality of Life in CAR-T Cell Therapy · 2026 · Related
  19. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial · Luc‐Matthieu Fornecker · 2022 · 80 citations · Cited by this paper
  20. Asciminib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Case Series and Review of Emerging Evidence · 2026 · Related
  21. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma · Yasuhiro Oki · 2014 · 54 citations · Cited by this paper
  22. Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: a meta-analysis of randomized controlled trials · Yue Yang · 2025 · 4 citations · Cited by this paper
  23. Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD · Chiara Rusconi · 2025 · 3 citations · Cited by this paper
  24. Untitled · Cited by this paper

Source: OpenAlex (CC0)